On November 1, Meredith Addy of AddyHart P.C. and I submitted an Amici Curiae brief to the U.S. Supreme Court on behalf of Freenome Holdings and New Cures for Cancers in support of the Petition for Certiorari in Athena Diagnostics v. Mayo Collaborative Services. If the Supreme Court does not take this case, it is unlikely to reconsider its decisions on Section 101 of the U.S. patent law. This may be our last gasp judicial effort. The Supreme Court takes cases raising inconsistencies in the law or a circuit split. We knew parties/amici would focus on the Federal Circuit’s “internal circuit split,” so we took a different approach and urged the Court to resolve five critical inconsistencies in the law, summarized below.
- Noncompete Agreements: Finding the Balance Between Reasonable Restraints and Free Range Talent
- Building High-Quality Patent Portfolios in the United States and Europe: Part II – Software Patents
- Biden Executive Order’s Approach to SEPs Sells Out American Small Businesses and Innovators
- Billionaire Space Race Between Bezos and Branson (and Musk) Pushes Forward Next Generation of Spaceflight Innovation
- The Washington Football Team’s Trademark Journey: Over the Bumps and Full Speed Ahead
- COVID IP Waiver Attempts are Becoming Harder to Justify
- Coons and Hirono Raise Concerns Over Pride in Patent Ownership Act Penalties
- The Fintiv Deception: Leahy’s Legislative ‘Fix’ is Unwarranted in Light of Sotera Wireless
- An Ax(le) Needs Grinding: Can the Federal Circuit Turn the Wheel?
- India’s Prius Judgment and Trans-Border Reputation of Trademarks